These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 1949946)

  • 1. Comparative study of Saudi-marketed products and US drug labeling.
    Bawazir SA; al-Hassan MI; al-Khamis KI; Abou-Auda HS; Gubara OA
    DICP; 1991; 25(7-8):863-6. PubMed ID: 1949946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of prescribing information for generic drugs manufactured in the Middle East and marketed in Saudi Arabia.
    Gebran N; Al Haidari K
    Ann Saudi Med; 2006; 26(3):192-9. PubMed ID: 16861873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical information in drug package inserts in India.
    Shivkar YM
    J Postgrad Med; 2009; 55(2):104-7. PubMed ID: 19550054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A survey of top 200 drugs--inconsistent practice of drug strength expression for drugs containing salt forms.
    Prohotsky DL; Zhao F
    J Pharm Sci; 2012 Jan; 101(1):1-6. PubMed ID: 21905029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Critical Evaluation of Pharmacogenetic Information in Package Inserts for Selected Drugs Marketed in India and Its Comparison With US FDA-Approved Package Inserts.
    Pai SA; Kshirsagar N
    J Clin Pharmacol; 2016 Oct; 56(10):1232-42. PubMed ID: 26873003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A literature search on pharmacokinetic drug interactions of statins and analysis of how such interactions are reflected in package inserts in Japan.
    Saito M; Hirata-Koizumi M; Urano T; Miyake S; Hasegawa R
    J Clin Pharm Ther; 2005 Feb; 30(1):21-37. PubMed ID: 15659001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does Industry-Conducted All-Case Surveillance of Newly Approved Oncology Drugs Contribute to the Revision of Package Inserts in Japan?
    Suzuki A; Sato H; Sasaki Y
    Clin Transl Sci; 2019 Sep; 12(5):505-512. PubMed ID: 31062933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. On-label on the table: what the package insert informs us about the tolerability profile of oral atypical antipsychotics, and what it does not.
    Citrome L; Nasrallah HA
    Expert Opin Pharmacother; 2012 Aug; 13(11):1599-613. PubMed ID: 22017361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Consumer and health literacy: The need to better design tobacco-cessation product packaging, labels, and inserts.
    Weiss SM; Smith-Simone SY
    Am J Prev Med; 2010 Mar; 38(3 Suppl):S403-13. PubMed ID: 20176315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Early achievements of the Danish pharmaceutical industry--8. Lundbeck].
    Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
    Theriaca; 2016; (43):9-61. PubMed ID: 27491172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse-drug-event data provided by pharmaceutical companies.
    Cudny ME; Graham AS
    Am J Health Syst Pharm; 2008 Jun; 65(11):1071-5. PubMed ID: 18499882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Physicians' Desk Reference. Problems and possible improvements.
    Cohen JS; Insel PA
    Arch Intern Med; 1996 Jul; 156(13):1375-80. PubMed ID: 8678706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differences in pharmacogenomic biomarker information in package inserts from the United States, the United Kingdom and Japan.
    Shimazawa R; Ikeda M
    J Clin Pharm Ther; 2013 Dec; 38(6):468-75. PubMed ID: 23895776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The product label: how pharmacokinetics and pharmacodynamics reach the prescriber.
    Marroum PJ; Gobburu J
    Clin Pharmacokinet; 2002; 41(3):161-9. PubMed ID: 11929317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overpromotion of drugs in international product package inserts.
    Osifo NG
    Trop Doct; 1983 Jan; 13(1):5-8. PubMed ID: 6836735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The development and operation of a package inserts service system for electronic medical records].
    Yamada H; Nishimura S; Shimamori Y; Sato S; Hayase Y
    Yakugaku Zasshi; 2003 Mar; 123(3):201-9. PubMed ID: 12693022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utility and importance of animal data in drug product labels.
    Baldrick P
    Regul Toxicol Pharmacol; 2014 Aug; 69(3):546-57. PubMed ID: 24928564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Improvement of package insert CYP information for prescription drugs marketed in Japan].
    Hirata-Koizumi M; Saito M; Urano T; Miyake S; Hasegawa R
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2005; (123):12-8. PubMed ID: 16541745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of information on gender differences in the package inserts of prescription drugs in Japan.
    Maida N; Kondo S; Ogawa M; Hayashi N; Iwata H; Kobayashi N; Yamaura K
    Drug Discov Ther; 2024 Jan; 17(6):396-403. PubMed ID: 38105007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conformity of package inserts information to regulatory requirements among selected branded and generic medicinal products circulating on the East African market.
    Sillo HB; Masota NE; Kisoma S; Rago L; Mgoyela V; Kaale EA
    PLoS One; 2018; 13(5):e0197490. PubMed ID: 29787579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.